Chronic myelogenous leukemia: Clinical practice guidelines in oncology

Susan O'Brien; Ellin Berman; Kapil Bhalla; Edward A. Copelan; Marcel P. Devetten; Peter D. Emanuel; Harry P. Erba; Peter L. Greenberg; Joseph O. Moore; Donna Przepiorka; Jerald P. Radich; Russell J. Schilder; Paul Shami; B. Douglas Smith; David S. Snyder; Robert J. Soiffer; Martin S. Tallman; Moshe Talpaz; Meir Wetzler

doi:10.6004/jnccn.2005.0044

Chronic myelogenous leukemia: Clinical practice guidelines in oncology

Susan O'Brien, Ellin Berman, Kapil Bhalla, Edward A. Copelan, Marcel P. Devetten, Peter D. Emanuel, Harry P. Erba, Peter L. Greenberg, Joseph O. Moore, Donna Przepiorka, Jerald P. Radich, Russell J. Schilder, Paul Shami, B. Douglas Smith, David S. Snyder, Robert J. Soiffer, Martin S. Tallman, Moshe Talpaz, Meir Wetzler

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2005, an estimated 4,600 cases will be diagnosed, and 850 patients will die of the disease. The median age of disease onset is 53 years; however, CML occurs in all age groups, with an increasing proportion of younger patients in more recent series. ML progresses from a chronic phase to a rapidly fatal blastic phase, generally over 3 to 5 years. The blast phase is often preceded by a transition period, called the accelerated phase, which is marked by the acquisition of new cytogenetic abnormalities in 50% to 80% of patients. Several definitions of the accelerated phase of the disease are summarized.

Original language	English (US)
Pages (from-to)	732-755
Number of pages	24
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	3
Issue number	6
DOIs	https://doi.org/10.6004/jnccn.2005.0044
State	Published - Nov 2005
Externally published	Yes

Keywords

Acute lymphocytic leukemia
Allogeneic transplantation
Chronic myelogenous leukemia
Cytarabine
Hematopoietic stem cell transplant
Imatinib mesylate
Interferon
NCCN Clinical Practice Guidelines

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2005.0044

Cite this

O'Brien, S., Berman, E., Bhalla, K., Copelan, E. A., Devetten, M. P., Emanuel, P. D., Erba, H. P., Greenberg, P. L., Moore, J. O., Przepiorka, D., Radich, J. P., Schilder, R. J., Shami, P., Smith, B. D., Snyder, D. S., Soiffer, R. J., Tallman, M. S., Talpaz, M., & Wetzler, M. (2005). Chronic myelogenous leukemia: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 3(6), 732-755. https://doi.org/10.6004/jnccn.2005.0044

O'Brien, S, Berman, E, Bhalla, K, Copelan, EA, Devetten, MP, Emanuel, PD, Erba, HP, Greenberg, PL, Moore, JO, Przepiorka, D, Radich, JP, Schilder, RJ, Shami, P, Smith, BD, Snyder, DS, Soiffer, RJ, Tallman, MS, Talpaz, M & Wetzler, M 2005, 'Chronic myelogenous leukemia: Clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 3, no. 6, pp. 732-755. https://doi.org/10.6004/jnccn.2005.0044

@article{54f4a29bad764204aa51fd085e20a0d6,

title = "Chronic myelogenous leukemia: Clinical practice guidelines in oncology",

abstract = "Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2005, an estimated 4,600 cases will be diagnosed, and 850 patients will die of the disease. The median age of disease onset is 53 years; however, CML occurs in all age groups, with an increasing proportion of younger patients in more recent series. ML progresses from a chronic phase to a rapidly fatal blastic phase, generally over 3 to 5 years. The blast phase is often preceded by a transition period, called the accelerated phase, which is marked by the acquisition of new cytogenetic abnormalities in 50% to 80% of patients. Several definitions of the accelerated phase of the disease are summarized.",

keywords = "Acute lymphocytic leukemia, Allogeneic transplantation, Chronic myelogenous leukemia, Cytarabine, Hematopoietic stem cell transplant, Imatinib mesylate, Interferon, NCCN Clinical Practice Guidelines",

author = "Susan O'Brien and Ellin Berman and Kapil Bhalla and Copelan, {Edward A.} and Devetten, {Marcel P.} and Emanuel, {Peter D.} and Erba, {Harry P.} and Greenberg, {Peter L.} and Moore, {Joseph O.} and Donna Przepiorka and Radich, {Jerald P.} and Schilder, {Russell J.} and Paul Shami and Smith, {B. Douglas} and Snyder, {David S.} and Soiffer, {Robert J.} and Tallman, {Martin S.} and Moshe Talpaz and Meir Wetzler",

year = "2005",

month = nov,

doi = "10.6004/jnccn.2005.0044",

language = "English (US)",

volume = "3",

pages = "732--755",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "6",

}

TY - JOUR

T1 - Chronic myelogenous leukemia

T2 - Clinical practice guidelines in oncology

AU - O'Brien, Susan

AU - Berman, Ellin

AU - Bhalla, Kapil

AU - Copelan, Edward A.

AU - Devetten, Marcel P.

AU - Emanuel, Peter D.

AU - Erba, Harry P.

AU - Greenberg, Peter L.

AU - Moore, Joseph O.

AU - Przepiorka, Donna

AU - Radich, Jerald P.

AU - Schilder, Russell J.

AU - Shami, Paul

AU - Smith, B. Douglas

AU - Snyder, David S.

AU - Soiffer, Robert J.

AU - Tallman, Martin S.

AU - Talpaz, Moshe

AU - Wetzler, Meir

PY - 2005/11

Y1 - 2005/11

N2 - Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2005, an estimated 4,600 cases will be diagnosed, and 850 patients will die of the disease. The median age of disease onset is 53 years; however, CML occurs in all age groups, with an increasing proportion of younger patients in more recent series. ML progresses from a chronic phase to a rapidly fatal blastic phase, generally over 3 to 5 years. The blast phase is often preceded by a transition period, called the accelerated phase, which is marked by the acquisition of new cytogenetic abnormalities in 50% to 80% of patients. Several definitions of the accelerated phase of the disease are summarized.

AB - Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2005, an estimated 4,600 cases will be diagnosed, and 850 patients will die of the disease. The median age of disease onset is 53 years; however, CML occurs in all age groups, with an increasing proportion of younger patients in more recent series. ML progresses from a chronic phase to a rapidly fatal blastic phase, generally over 3 to 5 years. The blast phase is often preceded by a transition period, called the accelerated phase, which is marked by the acquisition of new cytogenetic abnormalities in 50% to 80% of patients. Several definitions of the accelerated phase of the disease are summarized.

KW - Acute lymphocytic leukemia

KW - Allogeneic transplantation

KW - Chronic myelogenous leukemia

KW - Cytarabine

KW - Hematopoietic stem cell transplant

KW - Imatinib mesylate

KW - Interferon

KW - NCCN Clinical Practice Guidelines

UR - http://www.scopus.com/inward/record.url?scp=33644832711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644832711&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2005.0044

DO - 10.6004/jnccn.2005.0044

M3 - Review article

C2 - 16316611

AN - SCOPUS:33644832711

SN - 1540-1405

VL - 3

SP - 732

EP - 755

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 6

ER -

Chronic myelogenous leukemia: Clinical practice guidelines in oncology

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this